INTRODUCTION
Lung transplantation has been available as a therapeutic option for patients with end-stage cystic fibrosis (CF) lung disease from the mid-1980s. Since this time, in excess of 700 CF patients have undergone the procedure worldwide, as recipients of heart-lung, double lung, or more rarely single lung cadaveric transplants. A small number of CF patients have received living donor lobar transplants, but this procedure has been performed rarely in the UK.
Survival following heart-lung or double lung cadaveric transplantation is poorer than for other solid organ transplants, with the International Registry reporting survival of 60-70% at 1 year and 30-40% at 5 years for both procedures1 (Figure 1 ). These survival figures vary little between major centres, and are improving only slowly. However, there is increasing evidence that correctly timed transplantation does provide patients with a significant increase in longevity, in addition to an improved quality of life2'3.
As the potential benefits of the procedure become better understood, the number of potential recipients is increasingly outweighing the number of suitable donors. This has the effect of increasing waiting times for organs, with a number of patients not surviving the waiting period. This is an international problem, affecting all solid organ transplants, and is unlikely to be resolved in the near future.
As post-transplant survival is relatively poor, patients must not be transplanted too early, or the potential survival benefit from the procedure is reduced. Conversely, if patients are accepted for transplantation too late, the likelihood of them receiving organs is reduced, with the assessment and acceptance for transplantation merely offering them false hope. The first goal of transplant assessment is, therefore, assessment of risk.
Furthermore, if patients with particularly poor posttransplant survival potential can be identified, they can either be counselled against transplantation, or offered tailored post-transplant care in an attempt to improve their outcome. The second goal of transplant assessment is, therefore, identification of absolute and relative contraindications. Street, [1988] [1989] [1990] [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] The potential risks and benefits of transplantation are not straightforward, and few patients have accurate knowledge of these issues at time of first referral. The third goal of assessment is therefore to provide the child and family with a balanced understanding of risk and benefit, as well as an understanding of the commitment to regular therapy and monitoring that are essential for optimal outcome. This goal can be expressed as 'obtaining informed consent'.
ASSESSMENT OF RISK
Given the limited survival following transplantation, most centres will only transplant patients with a life expectancy of 2 years or less, and a poor quality of life4'5. Determining life expectancy in CF is a difficult procedure, and is based on review of a variety of clinical and physiological measurements, including measurements of lung function, oxygen consumption at peak exercise, height, heightadjusted weight percentile, body mass index, frequency of hospital admission, plasma albumin concentration, plasma alkaline phosphatase concentration, arterial blood gases, white blood cell count, haemoglobin concentration, clinically detectable splenomegaly, clinically detectable hepatomegaly, and resting heart rate. All of these measurements have been suggested to be of prognostic significance in CF, with forced expiratory volume in 1 s (FEV1) being the most consistent predictor6-11. An FEV1 of 30% of predicted normal correlates with an expected life expectancy of 2 years or less12, but other factors such as young age, female sex, resting tachycardia, and rapidity of decline may also need to be considered. Cardiorespiratory Much of the recent literature on timing of acceptance for transplantation comes from the USA, where the procedure for allocating organs differs from the UK. In the USA organs are allocated according to a strict waiting list, with patients within a region waiting the longest time being allocated available organs. The waiting time is currently up to 2 years, and a number of patients die while awaiting organs. Transplant centres in the USA are therefore bound to list patients for transplant when their FEV1 falls to 30%, and possibly even sooner, as patients listed later than this may not survive until transplant. One recent study suggests that younger patients should be listed when their FEVy reaches 500/o13, though this has not yet become the policy of any centre. The allocation procedure in the UK differs, in that organs are offered to transplant centres by geography or rotation. Those centres then allocate them according to clinical need, with patients with the poorest clinical status being transplanted first. UK centres are not therefore obliged to list patients when they still have 2 years' predicted survival, but can delay listing until it is judged that the patient will receive the greatest overall benefit from the procedure.
Assessment of quality of life is even less exact than estimation of life expectancy, as there are no widely accepted measures of quality of life in childhood. Assessment is therefore made by the clinician in collaboration with other members of the transplant team, and takes account of ability to partake in daily activities such as schooling or social activity, exercise tolerance, time spent in hospital, and requirement for oxygen therapy. As far as practicable this assessment is taken from the child's perspective rather than from the parents, and detailed information from the referring centre is of great value. Although inexact, assessment of quality of life is an essential component of the risk assessment, and a child with an FEV1 of 30% is unlikely to be accepted for transplantation if they still maintain a good quality of life.
ABSOLUTE AND RELATIVE CONTRAINDICATIONS
There is little consensus over contraindications to transplantation, and this section describes the guidelines of our own centre, Great Ormond Street Hospital for Children (GOS). It is best to consider these factors as absolute contraindications, relative contraindications, and conditions that require pre-transplant assessment so that treatment can be modified. Absolute contraindicatiorns * Severe irreversible damage to other organs-particularly with regard to renal dysfunction, as immunosuppressive agents are unlikely to be tolerated in these patients.
Patients with hepatic disease are assessed individually.
Patients with neurological impairment are only refused transplant if we judge that transplant will not significantly improve their quality of life. * Malignancy-5 years disease free is required before transplantation can be considered. * HIV infection. allow them to undertake activities previously impossible. At worst it can shorten life, or provide false hope as children await a transplant that will never occur. Few families have this understanding of transplantation when they first attend for assessment, and a large portion of the assessment period is devoted to education. Our aim is that no child should be listed for transplantation with an unrealistic expectation of what it can provide, and that children considered too well for transplantation to be justifiable should understand the reasoning behind this decision. The reality is that transplantation assessment is such a stressful time that many families have difficulty absorbing all the information they are given, and require further input during a second or third visit.
THE ASSESSMENT PROCEDURE AT GREAT ORMOND STREET Initial assessment for lung transplantation involves a 3-4 day admission, during which the child and family undergo a series of assessments, investigations, and educational sessions. These include clinical assessment, psychosocial assessment, pulmonary function testing (spirometry, measurement of lung volumes, exercise testing), cardiac assessment (edhocadiogran and electrocardiogram), renal assessment (creatinine clearance), microbiology (cultures and serology), imaging (radiography and abdominal ultrasound), aand blood testng for renal and hepatic function, coaguopathy, crossmnatching, immunoglobulin levels and inflammatory markers.
Education is proided by our nurse specialist, pharmacist, dietician, and medical team. A meeting with the child and family is held on the final day, and the decision is based on the citeria detailed above, with risk assessment being based largely on clinical criteria and measurements of pulmonary function. Very few patients are discharged. These are patients who have decided against transplantation or who have been identified as having absolute contraindications.
A minority of patients are immediately accepted onto the active waiting list. These families will usually have further preparation, completion of documentation, and be issued with pagers before discharge. They will then be Figure 2 Outcome for children with cystic fibrosis assessed for lung transplantation at Great Ormond Street, 1988 Street, -1998 The majority of patients are placed on a provisional waiting list. These patients are then kept under regular review and will be regularly reassessed, usually at intervals of 6 months. Patients who are placed on the provisional waiting list have not been referred too early, and in many ways benefit from having being referred at this stage, as the extra period for assessment allows the child and family more time to understand the reality of transplantation.
THE GREAT ORMOND STREET EXPERIENCE
From April 1988 to November 1998, 224 CF patients have been assessed for lung or heart-lung transplantation at Great Ormond Street. Only seven have been discharged, 69 were immediately accepted for transplantation, while a further 69 were accepted after a period of review on the provisional waiting list. Patients placed on the provisional list demonstrated a wide variation in rate of clinical deterioration, suggesting that a policy of regular detailed reassessment is warrantedl5. Of the 138 patients accepted onto the active waiting list, 50 have received transplants, 78 have died prior to transplant, and 10 remain on the active list ( Figure 2 ). The majority of those receiving transplants did so within 1 year (median wait 0.58 years) and the majority of those who died while awaiting organs did so within 1 year (median survival 0.46 years) indicating that patients are listed at the appropriate time.
CONCLUSIONS
Lung or heart-lung transplantation is a valid therapeutic option for patients with severe CF lung disease, with the potenti-al to prolong survival and improve quality of life. In order to receive maximum benefit from the procedure, patients must be referred early enough for timing of reviewed,6--rnont,hly whAe on the act-ve list. Vo u m e 92 1 9 9 9 transplantation to be optimized, and must approach transplant with a realistic understanding of the potential risks and benefits. We recommend that patients with an FEV, of 30% predicted or less should be referred for transplantation, though girls, younger children, patients deteriorating rapidly, and patients with resting tachycardia may need to be referred sooner. There are very few absolute contraindications to transplantation, and if there is any uncertainty over whether referral is appropriate the concerns should be discussed with the transplant centre.
